JANX FY 2024 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+31.0% YoY

Gross Profit

$9M80.5% margin

Operating Income

-$99M-933.6% margin

Net Income

-$69M-651.6% margin

EPS (Diluted)

$-1.28

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$39M

Stockholders' Equity

$1.0B

Cash & Equivalents

$431M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$8M	+31.0%
Gross Profit	$9M	$6M	+39.2%
Operating Income	-$99M	-$73M	-35.4%
Net Income	-$69M	-$58M	-18.4%